Non-standard insulin analogues
US9487572B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 13, 2012 |
| Grant date | Nov 8, 2016 |
| Priority date | — |
| Expiry date | Jul 13, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2330/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An insulin analog comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analog or single-chain insulin analog containing a B domain containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. The analog may be an analog of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analog is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.